Chemicals and intermediates used in pharmaceutical manufacturing and drug development.
chemXplore tracks 177 projects in pharma, of which 69 are active.
Of the active ones, 37 expansion, 29 new construction and 3 revamp / retrofit.
25 active projects carry no start-up date yet. The dates themselves, per project, are for subscribers.
Specialty Medicines and new launches drove mid-single‑digit sales growth and core profit expansion, while a £328m restructuring charge cut total operating profit and EPS.
Automated IHC assay to distinguish malignant mesothelioma from mimics, registered with FDA and IVDR, and designed to preserve tissue for downstream molecular testing.
Phase 3 OASIZ‑301: dazodalibep (CD40L antagonist) showed greater ESSDAI reduction at Week 48 vs placebo, improved patient‑reported dryness, and similar safety across groups.
Compact benchtop immunoanalyser (~0.9 m²) with 36 reagent positions, planned >100-assay menu, Elecsys reagent compatibility, and reaction times ≤18 minutes for most tests.
Chugai links to Roche’s ASN Kidney Week 2026 media release presenting interim IMAgINATION data that show sefaxersen significantly reduced proteinuria.
Combination therapy produced 28.2‑month median OS, 63% ORR and 9.0‑month mPFS in first‑line PD‑L1+ recurrent/metastatic head and neck cancer, with responses across HPV status.
Phase III ARTEMIS‑011 showed median PFS 5.5 vs 1.4 months (HR 0.33); safety showed high rates of grade ≥3 TRAEs with Ris‑Rez versus chemotherapy.
Phase 3 TroFuse‑005 showed a 32% lower risk of death and 41% lower risk of progression or death, with a PDUFA target date of June 15, 2027.
Phase 3 KEYNOTE‑C93: pembrolizumab alone extended median PFS to 38.2 vs 8.4 months versus platinum doublet; results presented at ESMO and published in The Lancet.
Adds Kolibri NPLI platform to support complex inhaled therapies including biologics, and integrates formulation, device, regulatory and digital services for end‑to‑end development.
active all projects
The 8 with the most active projects, of 27 countries.
